Diffuse large B cell lymphoma (DLBCL) is an aggressive form of B-cell non -Hodgkin lymphoma (NHL) and the most common type of NHL. With its heterogeneous nature in clinical behavior, morphology and immunophenotype, reliable biomarkers are needed to accurately categorize the tumor subtypes. Recently, the team led by Dr. Scott has revealed the location of MYC rearrangement at base pair resolution by performing targeted sequencing of MYC, BCL2, BCL6 and IG loci. The team discovered a novel recurrent MYC partner, RFTN1, and identified clinically relevant architecture of MYC rearrangement in DLBCL (Chong et al., Blood Advances, 2018). To further dissect the subtypes of DLBCL, Dr. Scott and his team developed a new clinical assay based on a 104-gene double-hit signatures (DHITsig). The new assay, DLBCL90, identifies a clinically and biologically distinct group within GCB-DLBCL characterized by a gene expression signature of high-grade B-cell lymphoma with double/triple hit (HGBL-DH/TH-BCL2) and helps guide clinical management of this aggressive disease (Ennishi et al., J. Clin. Oncol, 2018). The aim of this program is to improve patient outcomes by comprehensively characterizing the aggressive B-cell lymphoma subtypes and developing clinically relevant assays.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.